Sanofi Pasteur starts clinical trial of PER.C6-based H7N1 vaccine

By Elaine Rigoli

Tampa, Fla., Sept. 19 - Sanofi Pasteur said it has within the framework of Fluplan, a collaborative research project funded by the European Commission, generated the first clinical trial lot of a new generation of H7N1 pandemic vaccine.

The company said this trial will broaden Sanofi Pasteur's pandemic preparedness program initiated with the development of H5N1 vaccines.

The H7N1 vaccine was produced at Sanofi Pasteur's Marcy l'Etoile facility in France using Crucell's PER.C6 cell-based technology, allowing an alternative production process expected to offer advantages over traditional manufacturing methods, according to a news release.

This phase 1 clinical trial, initiated in Bergen, Norway, is the first to assess the safety and ability to generate an immune response of a split, inactivated prototype pandemic H7N1 vaccine produced on cells, the release said.

Sanofi Pasteur, the vaccines business of the pharmaceutical company Sanofi-Aventis Group, is based in Lyon, France.

Crucell is a biotechnology company with headquarters in Leiden, the Netherlands.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.